Skip to content

Eleos Health develops AI documentation and workflow tools for behavioural healthcare, helping clinicians prepare session records and supporting administrative review within care organisations.

Introduce me to Eleos Health
Eleos Health name placeholder

Founders & company facts

Sources reviewed:

Reported cumulative funding

$128,000,000 · Source

This index includes companies with publicly reported total funding up to US$150 million. This is a reported total, not valuation, the latest round size or confirmation of an open round. Funding reviewed: .

Documented founding team

No confirmed founder names are included in this profile.

Founded
Not confirmed
Reported Israeli location
Not confirmed
Team range in directory
Not confirmed
Reported business model
Not confirmed

Selected disclosed financing

Selected transactions, with dates, funding types and reported participants.

Individual financing rounds have not been documented in this profile. A reported total is shown above when available.

Derived from the company's reported $68M cumulative funding in September 2023 plus its $60M Series C; the Series C release says over $120M. Source

Additional evidence used when reviewing the reported cumulative funding. Source

Company overview

Product & customers

Eleos Health develops AI documentation and workflow tools for behavioural healthcare, helping clinicians prepare session records and supporting administrative review within care organisations.

Commercial potential · editorial analysis

For Eleos Health, the commercial question is how behavioural health documentation supports paying customers over time. The opportunity involves fitting a clearly defined use case into an existing care or wellbeing workflow. A review should distinguish trials from paid adoption and examine the support and delivery work required as usage expands.

What to validate

When assessing Eleos Health, diligence should cover the intended use, appropriate clinical evidence, accessibility, privacy and the approval status required for the target market. Prospective users should ask for evidence from settings comparable to their own, including unsuccessful cases and costs, before drawing conclusions about deployment suitability.

Product source reviewed on . Company source

Optional cookies for analytics and marketing. You choose, and can change your choice anytime. Details & privacy